secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000950170-25-102387
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Q2 net loss $38.9M ($0.35/sh); Gilead collab truncated
-------------------------------------------------------------------------

- Net loss $38.9M ($0.35 per share) vs $25.6M ($0.24) in Q2 2024; revenue fell to $3.2M.
- Cash $180.8M; expects to fund operations into Q1 2027.
- Gilead collaboration research term trimmed from 7 to 5 yrs; $53.8M deferred revenue to be recognized in Q3 2025.
- First patients dosed in TNG462 combo with Revolution Medicines RAS(ON) inhibitors and TNG456 Phase 1/2.
- TNG462 monotherapy data expected 2H 2025; TNG260 clinical data also expected 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017025102387/0000950170-25-102387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017025102387/tngx-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-102387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer